Evaluation of glomerular filtration rate (GFR) is central to medical practice, research and public health. As investigators who developed the Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epi demiology Collaboration (CKDEPI) equa tions for estimation of GFR, and as leaders of national and international guideline com mittees and workshops on the use of esti mated GFR (eGFR), we take issue with the conclusions of Porrini 1 ), which discus ses the reliability of eGFR equations. These authors conclude that "eGFR is an unreli able tool to assess renal function in health and disease, as well as in clinical practice and research". Instead of eGFR, they recommend more frequent use of measured GFR (mGFR). We agree that eGFR may be imprecise; using the most accurate eGFR equations, the pro portion of eGFR values that are within 30% of mGFR values (P 30 ) generally does not exceed 90%, which is the performance goal for eGFR 2, 3 . We also agree that more frequent use of mGFR is desirable, and we applaud the work of Porrini et al. in implementing plasma clearance of iohexol in research stud ies. However, we regard their conclusions as flawed for several reasons.
First, their analysis includes studies that did not standardize assays for creatinine or cysta tin C, leading to unpredictable bias in eGFR values based on levels of creatinine (eGFR cr ), cystatin C (eGFR cys ) or both (eGFR cr-cys ), and to unreliable estimates of the accuracy of these equations. This flaw can only be avoided by limiting the analysis to studies that used standardized assays and equations devel oped or reexpressed for use with standardized assays 4 .
Second, they underestimate error in mGFR compared with 'true' GFR 5 , which contributes substantially to the errors reported in com parisons between eGFR and mGFR in both crosssectional and longitudinal studies. A systematic review by Soveri and colleagues 6 demonstrated bias and imprecision in all 4 Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
*e-mail: alevey@tuftsmedicalcenter.org current mGFR methods compared to the clas sical method of inulin clearance described by Homer Smith; P 30 often did not exceed 90%. Even the classical inulin clearance method is imprecise, with a coefficient of variation (CV) for repeated measures of approximately 7% 7 .
The smallest reported CVs using other mGFR methods are approximately 5-15%, gener ally with higher values for urinary clearance than plasma clearance methods [8] [9] [10] [11] [12] [13] [14] . Critically, for an unbiased mGFR method, a CV for repeated measures of 10% would be equiv alent to approximately 90% of mGFR within 15% of true GFR (P 15 of 90%). Third, they propose an alternative per formance goal for eGFR of P 10 > 90% compared with mGFR (90% of eGFR values within 10% of mGFR values). This goal is unrealistic, as it is not attainable for repeated measurements of mGFR using many methods.
Fourth, they fail to consider that clinical decisionmaking in most settings includes multiple factors in addition to eGFR 15, 16 . For many clinical decisions, a P 30 for eGFR cr compared with mGFR of 80-90% is adequate. If more accurate assessment is required, eGFR cys , eGFR cr-cys or mGFR are recommended as confirmatory tests, depending on their availability and the level of accuracy required for clinical decisionmaking.
In contrast to Porrini and colleagues, we conclude that both mGFR and eGFR have strengths and limitations and both can be improved. We recommend that clinicians, researchers and public health officials understand these strengths and limitations for wise use of both mGFR and eGFR.
There is a reply to this letter by Porrini, E. et al. Nat. Rev. Nephrol. https://doi.org/ 10.1038/s4158101902148 (2019).
